ADC Therapeutics (ADCT) Asset Writedowns and Impairment (2022 - 2026)
ADC Therapeutics (ADCT) posted quarterly Asset Writedowns and Impairment of $1.5 million for Q1 2026, up 18.22% year-on-year from $1.2 million in Q1 2025, and up 258.39% on a QoQ basis from $411000.0 in Q4 2025.
ADC Therapeutics (ADCT) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Asset Writedowns and Impairment for 5 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- Quarterly Asset Writedowns and Impairment rose 18.22% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 24.55% YoY) and the FY2025 annual result came in at $2.3 million, up 50.46% from the prior year.
- Asset Writedowns and Impairment grew to $1.5 million in Q1 2026 per ADCT's latest filing, from $411000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for ADCT reached as high as $1.9 million in Q2 2022 and fell as low as -$539000.0 in Q4 2022.
- A 5-year average of $637000.0 and a median of $482000.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment slumped 62.47% — and 2024, when it surged 1311.32%.
- Year by year, Asset Writedowns and Impairment stood at -$539000.0 in 2022, then jumped by 253.62% to $828000.0 in 2023, then tumbled by 41.79% to $482000.0 in 2024, then dropped by 14.73% to $411000.0 in 2025, then soared by 258.39% to $1.5 million in 2026.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $1.5 million, $411000.0, and $237000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.47 Mn |
| Mar 31, 2026 | 1.47 Mn |
| Dec 31, 2025 | 411,000.00 |
| Dec 31, 2025 | 411,000.00 |
| Sep 30, 2025 | 237,000.00 |
| Sep 30, 2025 | 237,000.00 |
| Jun 30, 2025 | 390,000.00 |
| Jun 30, 2025 | 390,000.00 |
| Mar 31, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | 482,000.00 |
| Dec 31, 2024 | 482,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Mar 31, 2024 | 748,000.00 |
| Mar 31, 2024 | 748,000.00 |
| Dec 31, 2023 | 828,000.00 |
| Dec 31, 2023 | 828,000.00 |
| Jun 30, 2023 | 727,000.00 |
| Jun 30, 2023 | 727,000.00 |